CoVariant - Understanding the determinants of mucosal immunity and optimizing the diagnosis of infection with SARS-CoV-2 variants

What are the objectives of this study? This study aims to improve the identification of SARS-CoV-2 infection as well as to better understand the immune response of infected people, particularly at the level of the respiratory mucosa. To do this, researchers need to collect nasal and nasopharyngeal swabs, blood, saliva and exhaled air samples. People are identified via the project's partner medical analysis laboratories, pharmacies and health centers carrying out COVID-19 screening tests. Who can participate? The persons concerned must: be over 18 years old have carried out a COVID test ≤ 4 days reside in Ile de France and can travel to the Institut Pasteur (Paris 15th), have a weight of at least 50 kg benefit from a Social Security system with the exception of State Medical Aid What does participation in the study involve? The CoVariant study is taking place at the ICAReB-Clin platform of the Institut Pasteur (Paris 15th). Participants not infected with SARS-CoV-2: 2 visits to be carried out according to the following schedule: The 1st visit (1 hour inclusion visit) will take place a maximum of 4 days after the test and will include a clinical examination, blood, saliva and nasopharyngeal samples and a collection of exhaled air. A 2nd visit (30 min) will take place a maximum of 3 months after inclusion and will include a clinical examination, blood and nasopharyngeal samples and collection of exhaled air. Participation in the study is for a maximum of 3 months. For participants infected with SARS-CoV-2: 4 visits to be carried out according to the following schedule: The 1st visit (1 hour inclusion visit) will take place either at the Institut Pasteur or at home if isolation is required. This visit will include a clinical examination, blood, saliva and nasopharyngeal samples and a collection of exhaled air. The following 3 visits (30 min follow-up visits) will take place 1 week, 1 month then 3 months after the inclusion visit. These visits will include a clinical examination, blood, saliva and nasopharyngeal samples and a collection of exhaled air. Participation in the study is 3 months. Participation compensation: A fixed compensation of €30 will be paid at the end of each visit to the Institut Pasteur. 2 methods of recruiting participants: - 1. Have you performed a COVID test in a Biogroup laboratory? - If you do not object to the analysis laboratory, your telephone details will be transferred to the CoVariant team at the Institut Pasteur. You have the right to refuse that these are transmitted and you can change your mind at any time thereafter, without having to give a reason. If your contact details are provided, a member of the CoVariant team will call you to: present the study to you, check if you can participate obtain your oral agreement to participate offer you an appointment for the inclusion visit within 4 days following your COVID test. By clicking on the links below you will have access to the complete information notices which you must read before agreeing to participate in this study. For infected people For uninfected people - 2. Have you performed a COVID test in a laboratory (non-Biogroup), a pharmacy or in a health center? - If you are interested in participating in the CoVariant study you can contact the ICAReB-Clin platform at the following address: Covariant@pasteur.fr. You have the right to refuse to participate or to change your mind at any time thereafter, without having to provide a reason. During your contact with the ICAReB-Clin platform, a member of the CoVariant team: will present the study to you, will check if you can participate will offer you an appointment for the inclusion visit within 4 days following your COVID test. By clicking on the links below you will have access to the complete information notices which you must read before agreeing to participate in this study. For infected people For uninfected people - 3. ICAReB-Clin offered you to participate in the study? - If the ICAReB-Clin platform has asked you to participate in the study and you are interested, a telephone interview will be carried out. You have the right to refuse to participate or to change your mind at any time thereafter, without having to provide a reason. During your contact with the ICAReB-Clin platform, a member of the CoVariant team: will present the study to you, will check if you can participate will offer you an appointment for the inclusion visit according to your availability